Amarin Reports Second Quarter 2019 Financial Results and Operational Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Amarin Corp. (AMRN) Tops Q2 EPS by 4c, Revenues Beat
July 31, 2019 5:44 AM EDTAmarin Corp. (NASDAQ: AMRN) reported Q2 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $100.8 million versus the consensus estimate of $99.54 million.
Record Total Revenue of $100.8 Million Achieved in Q2 2019Commercial Expansion Plans on Track in Anticipation of September 28, 2019 PDUFA Date for Vascepa®If Approved, Vascepa to Become First Prescription Therapy to Treat Patients with Underlying Cardiovascular Risk Beyond Cholesterol Management as Demonstrated in the REDUCE-IT Cardiovascular Outcomes StudyMillions of Patients in the U.S. Have Underlying Cardiovascular Risk Beyond Cholesterol... More